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A b s t r a c t
Atherosclerotic carotid artery stenosis (CS) continues to be a common cause of acute ischaemic stroke. Optimised medical ther-
apy (OMT), the first-line treatment modality in CS, may reduce or delay – but it does not abolish – CS-related strokes. As per current 
AHA/ASA and ESC/ESVS/ESO guidelines, carotid artery stenting (CAS) is a less-invasive alternative to carotid endarterectomy (CEA) 
for CS revascularisation in primary and secondary stroke prevention.
Ten-year follow-up from the CREST trial in patients with symptomatic and asymptomatic CS confirmed equipoise of CAS and 
CEA in the primary endpoint. Nevertheless CAS – using a widely open-cell, first-generation stent and first-generation (distal/filter) 
neuroprotection – has been criticised for its relative excess of (mostly minor) strokes by 30 days, a significant proportion of which 
were post-procedural. 
Atherosclerotic plaque protrusion through conventional carotid stent struts, confirmed on intravascular imaging, has been 
implicated as a leading mechanism of the relative excess of strokes with CAS vs. CEA, including delayed strokes with CAS. Different 
designs of mesh-covered carotid stents have been developed to prevent plaque prolapse. Several multi-centre/multi-specialty clin-
ical studies with CGurad MicroNet-Covered Embolic Prevention Stent System (EPS) and RoadSaver/Casper were recently published 
and included routine DW-MRI cerebral imaging peri-procedurally and at 30 days (CGuard EPS).
Data from more than 550 patients in mesh-covered carotid stent clinical studies to-date show an overall 30-day complication 
rate of ~1% with near-elimination of post-procedural events. While more (and long-term) evidence is still anticipated, these results 
– taken together with optimised intra-procedural neuroprotection in CAS (increased use of proximal systems including trans-carotid 
dynamic flow reversal) and the positive 12-month mesh-covered stent data reports in 2017 – are transforming the carotid revascu-
larisation field today.
Establishing effective algorithms to identify the asymptomatic subjects at stroke risk despite OMT, and large-scale studies with 
mesh-covered stents including long-term clinical and duplex ultrasound outcomes, are the next major goals. 
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Atherosclerotic carotid stenosis  
and ischaemic stroke 
Acute ischaemic stroke is the leading cause of pre-
mature mortality and morbidity worldwide for both men 
and women [1, 2]. Atherosclerotic carotid artery stenosis 
continues to be a major cause of acute ischaemic strokes 
[1–4]. Accordingly, patients with symptomatic carotid 
stenosis account for up to ~30–60% of subjects enrolled 
in contemporary clinical trials of carotid revascularisa-
tion [5–8]. Some of these patients develop symptoms of 
carotid stenosis-associated cerebral ischaemia despite 
optimised medical therapy (OMT) [5, 9–12], consistent 
with the concept that OMT may reduce or delay [10, 13], 
but does not abolish, the stroke risk in relation to carotid 
atherosclerosis [9, 10, 12]. Thus, carotid artery stenosis, 
accounting for ~15–20% of acute ischaemic strokes to-
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day [1–4], continues to be an important and modifiable 
risk factor for ischaemic stroke [1]. 
Stroke in relation to atherosclerotic carotid artery steno-
sis occurs through progressive (usually in a non-linear fash-
ion) narrowing and resultant hypoperfusion in the ipsilater-
al hemisphere secondary to an incompetent circle of Willis 
or plaque rupture or erosion and consequent thrombus 
formation. However, most often the stroke mechanism is 
embolic rather than haemodynamic [14, 15]. Contemporary 
vascular clinic data indicate, in medically-treated patients 
with a significant carotid stenosis, a stroke risk of ~2% per 
year [9]. Because the yearly stroke risk is cumulative, such 
a seemingly “low” (to some) risk indicates, for instance, for 
a 50-year old medically-treated person with asymptomatic 
carotid stenosis, an absolute stroke risk of ~40% by age 70. 
This is not negligible to the patient and family. And it 
should not be neglected by the physician who can either 
significantly reduce this substantial stroke risk with safe 
carotid revascularization, or refer the patient to anoth-
er physician/centre where carotid revascularization with 
a minimal procedural risk can be performed.
According to current guidelines [16, 17] and clinical 
practice [2–7, 18–20], the endovascular route of carot-
id revascularisation (carotid artery stenting – CAS) is an 
alternative to carotid endarterectomy (CEA) in symptom-
atic and asymptomatic patients with atherosclerotic ca-
rotid stenosis. 
CREST and its impact on carotid artery 
stenting
Recent 10-year follow-up data from the Carotid Re-
vascularisation Endarterectomy versus Stenting Trial 
(CREST) demonstrated – in 2502 patients with symptom-
atic or asymptomatic carotid stenosis randomised on 
a 1 : 1 basis to transfemoral CAS or CEA – no difference 
in the rate of the extended study primary endpoint (com-
posite of periproedural stroke up to 30 days, and any 
myocardial infarction (MI) death, or any subsequent ip-
silateral stroke  – hazard ratio 1.10, 95% confidence in-
terval (CI): 0.83–1.44) [21]. There was no difference be-
tween CAS and CEA in stroke rate after 30 days, and no 
difference – in any study endpoint – for symptomatic vs. 
asymptomatic patients [21]. 
For many evidence-oriented physicians, large-scale 
level 1 evidence with long-term follow-up settles firmly 
the role of CAS in carotid revascularisation for primary 
and secondary stroke prevention in relation to atheroscle-
rotic carotid artery stenosis. For others, concerned with 
the equipoise of the two procedures in CREST [22], release 
of 10-year CREST data has been the occasion to attempt 
to reignite the decade-long debate [23] on the relative im-
portance of individual composites of the CREST primary 
endpoint [24]. This is because in the absence of any sig-
nificant differences in major stroke or death between the 
two procedures, in CREST there was a relative excess of 
MI with CEA and a relative excess of (minor and occurring 
up to 30 days post procedure) strokes with CAS [21, 24]. 
Consistent with the signal from CREST, recent meta-anal-
ysis of over 6500 patients from five trials with a mean 
follow-up of 5.3 years confirmed that CAS, using first-gen-
eration carotid stents and mainly distal (filter) neuropro-
tection, was indeed associated with a relative excess of 
(mostly minor and occurring mostly peri-procedurally and 
up to 30 days) strokes (odds ratio (OR) = 1.50, 95% CI: 
1.22–1.84) [25]. In contrast, the risk of periprocedural 
MI was significantly lower with CAS than with CEA (OR 
= 0.45, 95% CI: 0.27–0.75) and the composite of death, 
stroke, MI, or cranial nerve palsy by 30 days was signifi-
cantly lower with CAS (OR = 0.75, 95% CI: 0.60–0.93) [25]. 
Follow-up of the CREST patients clearly demonstrated 
that both periprocedural MI (seen more frequently with 
CEA) and procedure-related stroke (which occurred more 
frequently in the CAS arm) were prognostically important. 
The risk of death at 4 years was higher after peri-proce-
dural stroke, hazard ratio 2.78; 95% CI: 1.63–4.76 [26]. 
Similarly, patients with MI showed a significantly higher 
4-year mortality, hazard ratio 3.40, 95% CI: 1.67–6.92; 
an effect that remained significant after adjustment for 
baseline risk factors [27, 28]. In addition, using different 
data-sets, arguments have been raised that “real-life” 
outcomes may be worse-than-CREST for CAS [29] as well 
as for CEA [30]. However, as procedural strategies and 
techniques have significantly evolved in the last decade, 
paralleled by a  further increase in the (endovascular in 
particular) operator experience, the discussion of histori-
cal data may be chiefly of a historical value today. 
Evolution of carotid revascularisation 
strategies after CREST
Fundamental changes in carotid revascularisation 
equipment and strategies after CREST include: (1) sub-
stantial improvements in intra-procedural brain pro-
tection in CAS (more effective distal protection devices 
and increased understanding of the efficacy and role for 
proximal protection, new proximal protection systems 
that avoid the aortic arch), (2) novel carotid stent designs 
(mesh-covered stents to minimise plaque prolapse and 
embolisation during and after the procedure), (3) tailor-
ing the neuroprotection device and stent type to the pa-
tient’s symptomatic status and plaque type, (4) better 
case selection for avoiding high-risk CAS, which may be 
lower risk for CEA such as severe arch (N.B. trans-carotid 
CAS overcomes the arch problem) and proximal vessel 
disease including tortuosity as well as lesional angula-
tion and length or highly calcific lesions, and avoiding pa-
tients with potentially severe consequences of the carot-
id baroreflex activation with CAS (such as concomitant 
severe aortic valve disease), and (5) increased under-
standing of the importance of coronary risk evaluation 
and work-up to minimise the risk of peri-procedural MI.
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A substantial body of clinical evidence indicates that 
proximal neuroprotection [31–34] including dynamic 
flow reversal [35, 36] can minimise the risk of intra-pro-
cedural cerebral embolisation [37–43]. According to “tai-
lored CAS” algorithms [5, 34, 37, 44, 45], proximal neu-
roprotection is preferred in endovascular management 
of symptomatic and high-risk asymptomatic lesions. 
Indeed, compared with use of a filter, proximal neuropro-
tection significantly reduced the number of microembolic 
signals (MES) (p < 0.0001) during lesion crossing (mean 
2; interquartile range (IQR): 0 to 4 vs. 18; IQR: 11 to 30), 
stent crossing (0; IQR: 0 to 1 vs. 23; IQR: 11 to 34), stent 
deployment (0; IQR: 0 to 1 vs. 30; IQR: 9 to 35), stent 
dilation (0; IQR: 0 to 1 vs. 16; IQR: 8 to 30), and the total 
MES number (16; IQR: 7 to 36 vs. 93; IQR: 59 to 136) 
[39]. Moreover, the proportion of patients with any MES 
was profoundly lower with proximal device versus filter 
in phases 3 to 5 (27% vs. 100%; p < 0.0001) [39].
It is important to note that the endovascular arm of 
CREST employed an extremely open-cell carotid stent 
[21, 25] (individual cell area of 11.48 mm2 – the largest 
cell size among commonly used conventional carotid 
stents [46]). The advantage of an open-cell design is that 
it conforms to tortuous anatomy well. However, the con-
cern over large cell size, as is the case with most open cell 
designs, is that post stenting the plaque has greater un-
constrained areas through which it can extrude through 
the stent tines and embolise intracranially causing post 
stenting cerebral infarct that can manifest as clinical 
stroke. Data from registries that used several conven-
tional carotid stent types indicate an increase in the risk 
of neurological events with an increase in cell area [46]. 
This was confirmed by analysis from Stent-Protected An-
gioplasty versus Carotid Endarterectomy in Symptomat-
ic Patients (SPACE-1) prospective trial data, focused on 
the impact of the stent design on peri-interventional 
complication rate. In SPACE-1, the stroke risk was sig-
nificantly higher in patients treated with an open cell 
stent (11.0%, 95% CI: 6.2–17.8%) in comparison to those 
in whom a  closed cell stent was used (5.7%, 95% CI: 
3.7–8.3%, p < 0.05), and the stent design appeared to 
have a  more important impact on CAS neurological 
complications than the protection device [47]. Similarly, 
analysis of adverse outcome predictors in 828 patients 
randomised to the CAS arm of the International Carotid 
Stenting Study (ICSS), demonstrated that use of an open-
cell stent conferred a  statistically significant two-fold 
higher risk of stroke by 30 days than use of a closed-cell 
stent (relative risk (RR) = 1.92, 95% CI: 1.11–3.33) [48]. 
There are theoretical grounds and there is some moder-
ate-scale evidence that hybrid stents, which combine the 
open-cell design advantage of high conformability (prox-
imal and distal stent section) with the closed-cell design 
of the mid-section of the stent aimed to cover the plague, 
may be non-inferior to closed-cell stents [49]. 
Recent individual patient data analysis of 1604 pa-
tients who underwent neuroprotected CAS in the Euro-
pean Registry of Carotid Artery Stenting (ERCAS) demon-
strated that the use of an open-cell design stent with 
a free cell area > 7.5 mm2 was associated with a signifi-
cantly increased 30-day stroke risk [50], highlighting the 
importance of carotid stent design in minimising neuro-
logical complications following CAS.
Not only was neuroprotection in the CAS arm of 
CREST limited to a distal device that needs to be deliv-
ered through the lesion prior to establishing temporary 
brain protection [24, 39, 51], but also the device was 
a first-generation filter subsequently implicated to pro-
vide a limited, suboptimal neuroprotective effect [38, 52, 
53]. Moreover, there has been increasing understanding 
that filters may not to be applicable to all patients and 
lesions when an endovascular revascularisation route is 
used as the primary strategy [5, 36–38, 42, 44]. A recent 
meta-analysis of 8 studies (357 patients) compared the 
results of distal filter cerebral protection vs. proximal 
balloon occlusion in preventing embolisation during CAS 
as evaluated by diffusion-weighted magnetic resonance 
imaging of the brain (DW-MRI) [40]. The incidence of new 
ischaemic lesions after CAS detected by DW-MRI was sig-
nificantly lower in the proximal protection group (effect 
size: –0.43; 95% CI: –0.84 to –0.02) [40], indicating an 
important role for proximal neuroprotection in increasing 
the procedural (but not post-procedural) safety of CAS. 
Indeed, the role of optimised neuroprotection to achieve 
a safe CAS procedure is increasingly understood and has 
impacted clinical practice, with proximal embolic protec-
tion used in ~50% or greater proportion of CAS proce-
dures in the leading CAS centres today [5, 7, 37, 43, 44]. 
CREST [24, 26] confirmed observations from other 
large clinical studies using conventional carotid stents [54] 
that a significant proportion of strokes seen by 30 days 
occurred after completion of carotid revascularisation 
procedure, when the temporary embolic protection device 
was no longer in place. Indeed, with conventional open- or 
closed-cell carotid stents, 40–80% of all adverse neurolog-
ical events by 30 days are post-procedural [26, 46, 54].
Serial DW-MRI cerebral imaging demonstrated 
post-procedural cerebral embolisation after CAS using 
conventional stents [55]. In transfemoral CAS, open-cell 
stent design was shown to be associated with a 2-fold 
increase (p < 0.001) in the risk of periprocedural cerebral 
embolisation [38], consistent with the clinical evidence 
for a  2-fold increase in stroke up 30 days with open-
cell vs. closed-cell conventional carotid stents [47, 48]. 
The post-procedural cerebral embolisation [38, 55] and 
post-procedural neurological complications [26, 46–48, 
54] have been linked to the atherosclerotic plaque pro-
trusion through the stent struts [56–59]. Atherosclerotic 
plaque prolapse occurs (depending on the visualisation 
technique such as angiography, intravascular ultrasound, 
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or optical coherence tomography) in up to 30–60% of 
conventional carotid stents and it may be reduced but 
not eliminated with the conventional closed-cell stent 
designs [56–59]. Recent systematic evaluation of a large 
patient series (328 consecutive patients, 48% symptom-
atic) with CAS accompanied by routine intravascular 
ultrasound imaging confirmed a  significant increase in 
plaque prolapse susceptibility with the unstable carotid 
plaque and open-cell stent use [8]. Plaque protrusion was 
strongly associated not only with new ischaemic lesions 
on DW-MRI but also with the clinical manifestation of 
perioperative ischaemic stroke (p < 0.0001), indicating 
the necessity to prevent plaque prolapse [8]. Mesh-cov-
ered carotid stents, designed to prevent plaque prolapse, 
have been developed and implemented in the clinical 
practice of CAS, leading to an increasing body of clinical 
evidence in the public domain today [5–7, 60–63].
Following CREST, surgical strategies have been evolv-
ing too. Today, in many centres elective CEA is preceded 
by clinical and/or imaging screening for relevant coro-
nary artery disease and is performed under local anaes-
thesia either as a rule [64] or in increased-coronary-risk 
patients [65] to minimise the risk of CEA-associated MI. 
Surgeons are increasingly adopting the endovascular 
route to resolve important vascular pathologies such as 
aortic aneurysms, aorto-iliac, ilio-femoral, and below-the-
knee atherosclerotic disease leading to limb ischaemia, 
and the endovascular route, to many today, is natural 
in every-day practice. In the carotid territory, it is most 
recently exemplified by an increasing adoption of CAS 
using surgical access via the common carotid artery and 
a robust (‘dynamic’) flow reversal system for temporary 
brain protection (trans-carotid arterial revascularisation 
– TCAR) [35, 36, 38, 42, 66]. 
Mesh-covered carotid stents to minimise 
intra-procedural and prevent post-
procedural cerebral embolisation: designs 
and bench data
Minimisation of intra-procedural [38, 40, 43, 67] and 
prevention of post-procedural [55] cerebral embolism 
that, in a proportion of patients, is manifested as clinical 
strokes [26, 46, 54] have become fundamental to CAS as 
a treatment strategy. For CAS to continue as a viable treat-
ment modality, the surgical community postulated the 
necessity to develop better stents [68, 69] and to increase 
the use of proximal rather than distal protection [68].
The use of ultra-closed cell stent systems (N.B. the ul-
tra-closed cell design is achieved with the technology of 
covering the nitinol frame with a mesh that can be made 
of different materials), on the other hand, can not only 
further reduce the risk of intra-procedural neurological 
complications but also, by preventing plaque protrusion 
through stent struts, can eliminate the post-procedural 
cerebral embolisation as manifested on routine DW-MRI 
[60]. This strategy has been termed intra- and post-pro-
cedural (sustained) “embolic prevention” [5, 10]. Sus-
tained embolic prevention is thus complementary to the 
classic intra-procedural “embolic protection” using the 
proximal (flow clamping or reversal) or distal (filter) tem-
porary devices [10].
As of today, three different mesh-covered stents have 
been developed, including (1) RoadSaver/Casper [70–72] 
(Terumo/Microvention), (2) CGuard Embolic Prevention 
Stent [60, 61, 70] (CGuard EPS, InspireMD), and (3) the 
Gore hybrid stent [70, 73, 74] (Gore). Apart from the dif-
ferences in the nitinol frame design (braided closed cell in 
RoadSaver/Casper, open cell in CGuard and the Gore hy-
brid stent), the three current double-layered carotid stent 
systems have other important design differences. These 
include the mesh material (braided nitinol in RoadSaver/
Casper, PET single-fibre knitted MicroNET in CGuard, and 
interwoven PTFE mesh in the Gore stent), the aperture size 
of the mesh pores (500 µm in the Gore stent, 375–500 
µm in RoadSaver/Casper, and only 150–180 µm in CGuard 
EPS), and the position of the mesh in relation to the nitinol 
frame (outside the frame for the CGuard EPS and Gore 
stent, and inside in the case of the RoadSaver/Casper) [60, 
61, 70, 72]. The RoadSaver/Casper stent delivery system 
is low-profile and is very flexible and, similar to the Wall-
stent, the stent is re-sheathable up to 50% of the released 
stent length, which may offer a procedural advantage to 
some operators. However, RoadSaver/Casper exhibits very 
significant elongation on implantation, reaching almost 
30% of the nominal stent length [72]. 
Unsurprisingly, when minimising the protective mesh 
cell size the system delivery profile increases because 
the more protective micro-cells per stent frame area unit, 
the more mesh “fibres” are needed. The protective mesh 
material needs to be packed, along the stent frame, in 
the delivery system, so (as a general rule) the smaller the 
mesh cell size, the larger the delivery profile. The Road-
Saver/Casper has the smallest delivery profile (5 Fr) with 
the Gore stent in the middle (5 Fr or 6 Fr delivery profile 
dependent on the stent diameter). The CGuard EPS offers 
the largest open cell nitinol frame size among the current 
carotid stent systems (21.66 mm2 [5]) combined with the 
smallest mesh micro-cell size (0.023–0.032 µm2), which 
corresponds to the pore size in filters used for distal pro-
tection at CAS, making the CGuard EPS (with 6 Fr outer 
diameter of the packed delivery system) the most “open” 
and, at the same time, the most “closed” cell carotid stent 
among the current designs [5]. CGuard EPS has a high 
radial force that is similar to the Precise stent (Cordis) 
and is higher than that of RoadSaver/Casper [61, 72]. On 
manufacturer-independent bench tests [61] CGuard EPS 
showed adaptation to vascular anatomies both in a step 
model and in a curved model that was superior to Road-
Saver/Casper [61, 71].
Due to its construction, the RoadSaver/Casper does 
not have a  tapered version. On the other hand, the 
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CGuard EPS, with the SmartFitTM technology, has a prop-
erty of self-tapering (“self-adaptation”), as demonstrat-
ed in bench tests [72] and confirmed on a  systematic 
angiographic core lab evaluation in a series of over 100 
CAS procedures [5]. Another CGuard EPS characteristic 
that may be important from the procedural standpoint is 
the lack of foreshortening or elongation both on bench 
tests [72] and in vivo [5, 72]; a feature that may offer an 
advantage particularly in anatomies that require precise 
stent placement [5]. It is thus important to realize that 
”mesh-covered” carotid stents form a very diverse family, 
and the fundamental design differences (including the 
mesh material and mesh position in relation to the stent 
frame) may translate into individual differences in em-
bolic prevention efficacy on DW-MRI (that may or may 
not be clinically significant) as well as the device healing 
profile (including the risk of thrombosis and restenosis 
[70]), and that the implantation technique may also play 
a role to ensure proper device embedding into the vessel 
wall that may be possible with some but not other devic-
es due to the mesh position and mesh material.
Diffusion-weighted magnetic resonance 
imaging and mesh-covered stent systems 
embolic prevention efficacy 
The DW-MRI-depicted cerebral microembolisation is 
widely accepted as an index of the quality of cerebral 
protection during and after carotid revascularisation pro-
cedure [43, 55, 60, 75]. The index (including prevalence of 
any new lesions, their size, and total number) is extreme-
ly sensitive because many small lesions totally resolve 
without any clinical sequelae [60]. Today, DW-MRI is an 
important tool in evaluating minimisation of intra-pro-
cedural embolisation with improved temporary neuro-
protection systems [35, 38, 40]. The DW-MRI is similarly 
fundamental in evaluating the efficacy of different stent 
designs, in reducing peri-procedural embolisation, and 
preventing delayed cerebral embolism [67]. On the other 
hand, there is increasing evidence that carotid plaque-re-
lated cerebral embolisation may have a negative effect 
on cognitive function [76] (and intervention may be 
beneficial provided minimal intervention-related brain 
embolism [76–81]). Understanding is thus increasing 
today that the total burden of DW-MRI-depicted micro-
embolisation in patients undergoing carotid revascular-
isation by CEA or CAS may be associated with transient 
cognitive decline [82]. In a  proportion of patients, part 
of the deficit may persist months after the intervention 
[82, 83]. Thus, any carotid intervention, to have a positive 
impact on brain function, needs to be associated with 
minimised cerebral embolism. 
To date, the only published study with routine, 
per-protocol DW-MRI evaluation in all study patients 
rather than selected subjects appears to be the Carot-
id Embolic Protection Using MicroNET (CARENET) Multi-
centric Trial [60]. CARENET demonstrated a low peripro-
cedural embolism rate (37%) with an extremely small 
lesion size (0.039 ±0.08 cm3) [60]. With the small lesion 
size with routine CGuard MicroNET-covered EPS use, 
there was resolution of the peri-procedural lesions by 
30 days, and near-elimination of any post-procedural em-
bolism with only one new minor (0.116 cm3) lesion in re-
lation to the 48-h scan [60]. Comparison of the CARENET 
and PROFI data for patients treated under similar distal 
neuroprotection indicates a ~2-fold reduction in the prev-
alence of any DW-MRI lesion(s) and over 10-fold reduc-
tion in mean lesion volume when CGuard EPS rather than 
a conventional carotid stent is used [60, 75]. Recently, the 
DW-MRI findings from the CARENET trial have been rep-
licated by the Torino Vascular Radiology Group [84], who 
reported the  new DW-MRI lesion prevalence of 36.5% 
and an average 0.55 lesions per patient with median le-
sion volume of 0.040 cm3 (IQR: 0.025–0.050 cm3) using 
the CGuard EPS [84]. For the RoadSaver/Casper stent, 
the Torino Group found DW-MRI lesion prevalence of 
37.5%, with an average 1.3 lesions per patient, and me-
dian lesion volume of 0.076 ml (IQR: 0.064–0.138 cm3) 
[84]. Most recently, the IRON-GUARD study reported new 
post-procedural DW-MRI lesions in only 12 (19.6%) out 
of 61 patients subjected to DW-MRI imaging in CAS us-
ing CGuard EPS and mainly distal EPD [63].
Mesh-covered carotid stents: accumulating 
clinical evidence 
The article by Machnik et al. [62] in the current is-
sue of the Journal provides an important contribution 
to the growing clinical evidence for a  low neurological 
complication rate with the novel mesh-covered [10, 69] 
carotid stents. The single stroke in the series of mainly 
symptomatic (51.2%) patients, treated by these opera-
tors [62] using the Roadsaver/Casper stent [71, 72] under 
predominantly proximal (65.8%) embolic protection, was 
a  minor stroke that occurred after the common carot-
id artery cannulation with guiding catheter, i.e. prior to 
stent insertion and implantation [62]. 
With the patient series by Machnik et al. [62], the 
present body of clinical evidence has grown, consider-
ing studies that included at last 30 patients, to 551 CAS 
patients treated with mesh-covered carotid stents. This 
involved 190 subjects treated with Roadsaver/Casper [6, 
7, 62] and 361 CAS patients treated using CGuard EPS 
[5, 60, 61, 63]. These studies enrolled up to ~50% of 
symptomatic patients [5, 62] and were inclusive, in the 
all-comer series [5], of patients with acute symptoms of 
cerebral ischaemia (TIA or acute stroke in transition [5]). 
Inclusive of the periprocedural neurologic events that oc-
curred prior to stent placement, 30-day follow-up in those 
551 CAS patients (558 CAS procedures) showed only 
6 peri-procedural strokes (1.08%) [5–7, 60–63] and only 
1 (0.18%) post-procedural stroke, which occurred in a pa-
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tient with concomitant atrial fibrillation in the absence 
of adequate anticoagulation [6]. Thus the overall 30-day 
event rate was only 1.26% [5–7, 60–63]. These results are 
remarkable, particularly as reassuring 12-month reports 
from the CGuard EPS studies are arriving in the public do-
main in 2017 [85, 86]. At this point, it may be premature, 
however, to call the conventional carotid stents a histor-
ical footnote because still more evidence and longer fol-
low-ups are required [87].
Mesh-covered carotid stents: what further 
evidence do we need?
At the present stage, the mesh-covered carotid stent 
field, with data from over 550 patients and an overall 
procedural event rate of ~1% with near-elimination of 
post-procedural events during stent healing [5–7, 60–63], 
is ready for a  formal statistical overview of the results 
using individual patient data from the published studies. 
While this important clinical evidence (supplemented by 
routine DW-MRI data in all consecutive patients in one 
trial [60] and DW-MRI imaging in some patients in other 
studies [7, 61, 63, 84]) is already transforming the carotid 
revascularisation field, it is not sufficient to firmly estab-
lish the role of the novel technology [87]. 
Randomised studies would be particularly welcome 
because these are the ones that can provide ‘ultimate’ 
level-1 evidence [87], despite the fact that the lesson 
from CREST [21, 24] shows that acceptance of the study 
message may depend on what the message is [22]. As 
we contemplate future trials, it is important to under-
stand that the data from the randomised studies either 
in terms of clinical endpoints or intervention-associated 
DW-MRI lesion incidence, intensity, total lesion number, 
and size, will no doubt continue to play an important role 
as a  clinically-relevant surrogate endpoint [10, 75, 81]. 
Outcomes will critically depend on what patients (symp-
tomatic vs. asymptomatic, proportion of symptomatics) 
and lesions (not critical, stable, but angiographically sig-
nificant “to meet” the revascularisation indications vs. 
increased-embolism-risk, ulcerated, or thrombus-con-
taining/critical stenoses [10]) are enrolled and undergo 
randomisation. To demonstrate unequivocally the benefit 
of the new technology, the randomised studies “should” 
include the high (embolisation)-risk subjects because this 
is the group that expected to show the most profound 
difference after randomisation. While including high (em-
bolisation)-risk subjects is right (and required) from the 
point of study methodology, it may be questionable from 
the ethical standpoint [10]. This is particularly relevant 
because the data already available in the public domain 
indicate ~50% reduction in the incidence of cerebral em-
bolisation and ~10-fold reduction in mean lesion volume 
[60] when comparing the MicroNET-covered stent to 
a conventional carotid stent design used under the same 
type of temporary neuroprotection [75]. This concern may 
be somewhat mitigated by enrolling only those patients 
who are high risk for CEA, since many patients at high risk 
for CEA can be safely treated with CAS. Randomised trials 
remove the treatment selection bias but, as demonstrat-
ed by several recent examples in cardiovascular medi-
cine, they are greatly sensitive to patient selection bias 
[88, 89]. Patient selection bias may lead paradoxically to 
removing from the study (“patients not subjected to ran-
domisation”) those to whom the evaluated intervention 
is predominantly addressed [88, 89]. For instance, in the 
recent TASTE study one of the main reasons to exclude 
subjects with thrombus-containing coronary lesions from 
the cohort undergoing randomisation in a major clinical 
trial of coronary thrombus extraction in acute myocardi-
al infarction [88] was thrombus burden requiring, in the 
operator’s judgment, thrombus aspiration/removal. This 
was not indicated in the study inclusion/exclusion crite-
ria but it was listed as one of the principal reasons why 
patients meeting the inclusion criteria did not undergo 
randomisation [88]. While this was no doubt right ethical-
ly, it was clearly wrong methodologically, resulting in low-
risk subject enrolment and (unsurprisingly) an apparent 
“lack of benefit” of thrombus aspiration [89], particularly 
because the study was focused on a low-incidence end-
point of mortality [88]. While this provided zero evidence 
for the futility of routine consideration of thrombus aspi-
ration in acute myocardial infarction, it led (surprisingly) 
to a “downgrade” in the role of this intervention in the 
guidelines from Class IIa (weight of evidence in favour of 
usefulness/efficacy – intervention should be considered) 
[90] to Class IIb (usefulness/efficacy is less well estab-
lished – intervention may be considered) [91] because of 
the new “randomised study evidence”. The mesh-covered 
stent technology requires awareness to avoid a  similar 
trap because, for many CAS operators, it might be already 
ethically unacceptable today to randomise high-embo-
lism-risk patients (such as symptomatic or with throm-
botic lesions) to an open-cell carotid stent vs. a  Mi-
croNET-covered stent [5, 10], whereas the randomised 
study outcome may be critically dependent on inclusion 
of such high (embolisation)-risk subjects, particularly if 
focused on clinical end-points such as peri-procedural 
stroke and stroke during device healing (30-day stroke). 
On routine DW-MRI cerebral imaging, CGuard EPS 
system use was associated with > 50% reduction in the 
incidence of peri-procedural DW-MRI lesions and > 10-
fold reduction in average lesion volume [60, 74]. With the 
DW-MRI randomised data desired (but due to cost and 
logistics unlikely to be performed on a very large scale), 
any future comparison should correct for the proximal 
vs. distal temporary protection type (which plays a role in 
minimising the intra-procedural but not post-procedural 
cerebral embolisation [31, 35, 36, 38, 39, 40, 43]) and the 
type of lesion(s)/symptomatic status. 
Because evidence from clinical studies should be ap-
plicable to routine clinical practice, the role of all-comer 
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study protocols is increasingly understood in cardiovas-
cular medicine [5, 92] to minimise the proportion of trial- 
unrepresented patients [88, 89] to whom the tested in-
tervention is designed to apply. Routine access to tools 
that enable achievement of CAS 30-day complication rate 
≤ 1% in truly all-comer populations comprised of a major-
ity of symptomatic patients and including only increased-
stroke-risk asymptomatic patients [5], transforms the 
carotid revascularisation field [10, 93]. All-comer carotid 
referral tracking in a tertiary cardiovascular centre sug-
gested recently that > 90% (not all) contemporary carotid 
stenosis patients with NeuroVascular Team-determined 
indication to revascularisation (cohort including > 50% 
symptomatic patients, whereas the asymptomatic pa-
tients required at least one increased stroke-risk crite-
rion) can be safely and effectively treated using the en-
dovascular route and a  mesh-covered carotid embolic 
prevention stent system [5]. On the other hand, there 
are patient subsets where, for a vascular surgeon, CAS is 
clearly preferred over CEA due to anatomical or co-mor-
bidity criteria [6]. There is (and will remain!) a group of re-
vascularisation-indicated carotid stenosis patients who 
are natural candidates for surgery, a group – on the other 
side of the spectrum – with preferred endovascular man-
agement [6], and a very large group in the middle that 
can be managed with either method [5]. 
The multicentric multi-specialty CARENET trial 
demonstrated evidence for near-elimination of new le-
sion occurrence during the MicroNet-covered CGuard 
EPS healing period [60]. Thus, systematic peri-procedural 
and 30-day DW-MRI data on the two other mesh-covered 
stent systems (RoadSaver/Casper and the Gore hybrid 
stent) in cohorts of unselected patients are awaited to 
confirm the anti-embolic efficacy of these stents and to 
see whether there is any signal of a potential effect of de-
sign differences on embolic prevention efficacy [70, 84]. 
It remains to be determined whether the stent de-
sign and mechanical properties differences are import-
ant in terms of clinical safety and efficacy including, for 
instance, the risk of stent thrombosis or restenosis [94]. 
Moreover, the stent implantation technique (including 
post-dilatation to maximise embedding) may play a role. 
The double-layer stent design is naturally associated 
with permanent implantation of more material than in 
the case of a single-layered traditional carotid stent. This 
might, at least with some designs, affect stent healing 
and might, at least in theory, be related with a higher-
than-in-a-single-layer stent propensity to stent thrombo-
sis and restenosis. The thrombosis risk may be further 
influenced by the stent design through the combined 
thickness of the two layers (that significantly differs 
with different “mesh-covered” stent designs) and with 
the implantation technique, both resulting in a higher or 
lower malapposition rate. The combined thickness of the 
double-layer may influence the device healing duration. 
Similarly, the use of braided mesh design as opposed to 
non-metallic materials for enhanced plaque coverage 
with increased metal surface area exposed to platelets in 
the blood stream may pose unclear risks for stent throm-
bosis or delayed re-stenosis. In that context, optimal 
implantation technique (including the post-dilatation/
optimisation strategy [5]) and duration of clopidogrel 
use in addition to life-long aspirin, or the place of other 
drugs, such as ticagrelor, with the different stent designs 
remains undetermined [10]. 
During CAS, cerebral embolisation can (and does, al-
beit not in all patients) occur at the stage of aortic and 
target artery cannulation, guide catheter or sheath place-
ment, lesion wiring, filter crossing (for distal-protected 
CAS), predilatation (if performed), stent placement 
across the lesion, and stent post-dilatation as well as 
post implantation through plaque protrusion [39, 51]. Be-
cause, with the dual-layer stent design, the mesh offers 
protection against plaque material cerebral embolisation 
only starting with the stent post-dilatation phase, it is 
certainly premature to call off the temporary brain pro-
tection devices in CAS using dual-layer stent systems [6]. 
This is particularly relevant in the absence of any criteria 
for temporary neuroprotection device use (vs. non-use) 
[6] and because the embolic material (unsurprisingly in 
the context of emboli-generating CAS stages prior to es-
tablishing the mesh protection) continues to be present, 
albeit at an apparently lower rate [5, 37], in the intra-pro-
cedural (temporary) protection systems employed in CAS 
employing exclusively the novel stent generation [5]. 
Therefore, the concept of “no-need-for-neuroprotection 
device” with a dual-layered stent use [6], although defi-
nitely attractive to some operators, requires large-scale, 
properly designed investigation with routine DW-MRI 
imaging before any potential application of the strategy 
in some patient/lesion subsets, such as the treatment 
of conventional carotid stent in-stent restenosis (note 
the need to differentiate between true restenosis and 
neo-atherosclerosis) or primary stenting of a  fibrotic 
non-critical lesion (in the case of a clinical indication for 
revascularisation). It is also important to realise that the 
supposedly “benign” subset of conventional carotid stent 
restenotic lesions include instances of severe neo-ath-
erosclerosis [66] (continued intraluminal growth of the 
atherosclerotic plaque between the struts of the conven-
tional, uncovered, stent struts – up to the point of inter-
vention-requiring lumen compromise, clinical symptoms, 
or signs of embolisation on brain imaging) with a  very 
high risk of intraprocedural cerebral embolism [66].
Another important issue in the emerging field is to 
establish the role of direct carotid artery angioplasty and 
stenting (trans-carotid arterial revascularisation – TCAR, 
using surgical vascular access and endovascular dynamic 
flow reversal, which is highly effective in minimising in-
tra-procedural cerebral embolisation [35, 36, 38, 42, 65]) 
in combination with the novel dual-layer carotid stent 
technology for sustained embolic prevention. Initial ex-
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perience of TCAR CAS combined with MicroNET-covered 
CGuard EPS use in a high cerebral risk cohort (73% symp-
tomatic lesions, contralateral internal carotid artery oc-
clusion in 27%, ipsilateral ischaemic cerebral lesions on 
baseline DW-MRI in 100% of subjects), evidence by rou-
tine peri-procedural DW-MRI cerebral imaging combined 
with post-procedural DW-MRI extended to 90 days after 
(64% of procedures under local anaesthesia, dynamic 
flow reversal time from 6 min 20 s to 11 min 30 s, medi-
an 7 min 50 s), showed – with 100% clinical and neuro-
logical follow-up and 100% DW-MRI cerebral imaging at 
90 days – (1) no neurological or other complications, (2) 
near-elimination of peri-procedural cerebral embolism 
(only 0.36 DW-MRI lesion per patient), and (3) total elim-
ination of post-procedural cerebral embolism throughout 
the 90-day [66] period that exceeds stent healing dura-
tion [70]. This is consistent with the concept that the two 
technologies (TCAR dynamic flow reversal plus CGuard 
MicroNET-covered EPS), when combined, act in a  com-
plementary fashion (efficient capture and removal of 
intra-procedural debris with TCAR plus minimisation of 
intra-procedural embolism and sustained elimination of 
post-procedural embolism with CGuard EPS) and may be 
extremely efficient together [66], leading to a significant 
impact on evolution of the carotid revascularisation field.
Last but not least, an urgent, multi-specialty, and 
large-scale endeavour, involving neurologists, neuroin-
terventionalists, vascular surgeons, radiologists, cardi-
ologists, and angiologists is greatly needed to close the 
embarrassing gap in prospectively validated evidence to 
determine the optimal management paths for subjects 
with asymptomatic carotid stenosis including effective 
risk-stratification tools [9–12, 95, 96]. 
Conclusions
Atherosclerotic plaque protrusion through conven-
tional carotid stent struts [8, 56–59] has been identified 
as a leading mechanism of post-procedural cerebral em-
bolisation [55] and post-procedural adverse neurological 
events seen with the prior generation of carotid stents 
[47, 48, 50, 54]. Vascular surgery key opinion leaders 
have repeatedly indicated that the safety of CAS needs 
to be improved before CAS can be routinely applied by 
surgeons as an alternative to CEA [68, 69], and that the 
CAS role in carotid revascularisation would be fully es-
tablished only with an increased use of proximal neuro-
protection systems and the development of novel “ul-
tra-closed” cell stent systems [68]. 
Evidence is accumulating today for an adequate an-
swer from the endovascular community (with a  highly 
significant impact from endovascular-minded surgical col-
leagues and centres [5, 6, 63]) to the surgical postulate 
of improved carotid stent designs [68, 69] (to minimise 
intra-procedural embolism and prevent post-procedural 
embolisation [60]) and wider acceptance of more effective 
embolic protection such as proximal protection devices for 
higher (embolic)-risk patients in particular [6, 34, 36, 66]. 
The spring of improvements in carotid stent design [60, 70, 
72] and increased understanding of the role of optimised 
temporary brain protection at CAS [31–34, 36, 39, 40, 42, 
97], taken hand-in-hand with improvements in medical 
therapy [13], is already turning into the summer of routine 
clinical applications to prevent carotid atherosclerosis-re-
lated strokes. Emerging clinical experience indicates that 
the long-awaited [68, 69] technological advancement of 
double-layer “mesh” stents has widely re-opened the en-
dovascular route viability to the majority of patients with 
carotid stenosis and NeuroVascular Team-recommended 
[5, 10] indication to carotid revascularisation. 
Large-scale level 1 evidence for the efficacy of du-
al-layer carotid stent systems including clinical end-
points would be highly desirable, similar to the need to 
prospectively establish the role of intervention in asymp-
tomatic carotid stenosis [9–11, 95] and tools to identify 
increased-stroke-risk subjects to target the intervention 
to those most likely to benefit from it [12, 81, 96]. Expe-
rience from prior large-scale work, however, shows that 
such studies may be bound to practically suffer from the 
problems of effective recruitment volume/patient cross 
over and funding [24, 98, 99]. Selection bias-free ran-
domisation could be considered either unethical (in the 
case of high-risk lesion randomisation in a study employ-
ing prior generation single-layer stent(s) now DW-MRI 
evidenced to be associated with cerebral embolisation 
significantly exceeding, in both incidence and volume, 
that of a mesh-covered stent system [5, 60]), or the study 
would be a priori likely to be inconclusive (in case of low-
risk patient lesion randomisation). Cerebral DW-MRI im-
aging is going to continue [35, 38, 40, 43, 55, 60, 67] to 
provide a sensitive and clinically-relevant [76, 79, 80, 83] 
surrogate in the evaluation of novel carotid revasculari-
sation technologies and treatment strategies. 
Because knowledge from CREST has led to the evolu-
tion of both CAS and CEA, any continuation of the discus-
sion based on the CREST composite endpoint individuals 
(“would you rather have a (minor) stroke (with CAS)?” or 
“would you rather have a myocardial infarction (MI) (with 
CEA)?”) [22] is becoming obsolete today because such a 
discussion is largely irrelevant to contemporary knowl-
edge and practice. The Gordian knot of the relative im-
portance of the composite endpoint individuals in CREST 
[22, 23] is getting cut by the progress in endovascular 
medicine and surgery. There are, and will remain, patient 
and lesion subsets that will be better off with endovascu-
lar management and, on the other side of the spectrum, 
patient and lesion subsets that should be treated with 
surgery as a first-line strategy. But because the common 
area is large, patients and families should be given ac-
cess to full and unbiased information to make conscious 
choices [100], taking into account the technological de-
velopments and new medical knowledge arising from 
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contemporary (rather than historic) studies. Routine ac-
cess to tools and techniques that enable achievement 
of CAS complication rates of ~1% at 30 days [5–7, 10, 
60–63, 93] are transforming the endovascular carotid 
revascularisation field. In the (not remote) past, when 
different revascularisation techniques preferentially (al-
most) “belonged” to different specialties, a question of 
“how? (should carotid revascularisation be performed)” 
was effectively the question of “who? (should perform 
carotid revascularisation)”. This may have led to a bias in 
how the particular revascularisation strategy/technology 
was being presented to referring communities (such as 
neurology or non-interventional vascular medicine), po-
sitioned in the guidelines and, effectively, reimbursed (in-
cluding implementation of specialty-selective reimburse-
ment pathways in some healthcare systems). 
Today, with a  growing proportion of endovascu-
lar-minded surgeons who routinely apply endovascular 
techniques in their every-day practice to treat common 
vascular pathologies, and with the advanced stent tech-
nologies [5–7, 60–63] that enable sustained embolic pre-
vention [60, 66] and improved peri-procedural cerebral 
protection strategies [35–38, 43–45, 65, 66, 101], the sur-
gical community considers CAS a viable prospective treat-
ment modality in carotid revascularisation [93, 97]. Rather 
than acutely treated (which is generally accepted despite 
the fact that, for many patients, it comes unfortunately too 
late to avoid clinically-relevant brain damage [3–5]), carot-
id stenosis-related strokes should be safely and effectively 
prevented [10–12]. The spring of technological progress is 
now turning into the summer of routine clinical applica-
tions. “How?”, “using what technology?”, and “with what 
experience and expertise?” should, at last, matter more 
than “who?” should be performing carotid artery revascu-
larisation in acute stroke management as well as in prima-
ry and secondary stroke prevention. 
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